Table 4.

Comparison of RECIST 1.1 and mRECIST

Response in target lesions	RECIST 1.1	mRECIST
Complete response	Disappearance of all target lesions	Disappearance of any intratumoral arterial enhancement in all target lesions
Partial response	At least a 30% decrease in the sum of diameters of target lesions, taking as a reference the baseline sum of the diameters of the target lesions	At least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions, taking as the reference the baseline sum of the diameters of the target lesions
Stable disease	Any case that did not qualify for either partial response or progressive disease	Any case that do not qualify for either partial response or progressive disease
Progressive disease	An increase ≥20% in the sum of the diameters of target lesions, taking as the reference the smallest sum of the diameters of the target lesions recorded since treatment started	An increase of ≥20% in the sum of the diameters of viable (enhancing) target lesions, taking as the reference the smallest sum of the diameters of viable (enhancing) target lesions recorded since treatment started

Lymph nodes identified as target lesions should always have the actual short-axis measurement recorded.